Evidence summary on type 2 diabetes

  • The prevalence of diabetes is increasing, with an estimated 5% of Australians currently diagnosed with the chronic disease.1
  • Diabetes impacts quality of life, life expectancy and morbidity as a result of microvascular complications (retinopathy, nephropathy and neuropathy) and the increased risk of macrovascular complications (ischaemic vascular disease, stroke and peripheral vascular disease).2
  • Good glycaemic control reduces the development or progression of diabetes complications and can improve quality of life.2
  • About 60% of people with type 2 diabetes have cardiovascular disease and around 65% of all cardiovascular disease deaths in Australia occur in people with diabetes.3
  • Addressing lifestyle factors, blood pressure and blood lipids are just as essential, as they seem even more effective than glycaemic control in reducing the risk of cardiovascular complications.4
  • Reducing risk of cardiovascular events in people with type 2 diabetes requires concurrent management of lifestyle factors, blood pressure, lipids and blood glucose.1
  1. Australian Institute of Health and Welfare. Diabetes. 2016. [Online] (accessed 31 May 2016).
  2. Colagiuri S, Dickinson S, Girgis S, Colagiuri R. National Evidence Based Guideline for Blood Glucose Control in Type 2 Diabetes. Diabetes Australia and the National Health and Medical Research Council, 2009. [Online] (accessed 26 July 2012).
  3. Shaw J, Tanamas S. Diabetes: the silent pandemic and its impact on Australia. Baker IDI Heart and Diabetes Institute, 2012. [Online] (accessed 25 July 2012).
  4. National Prescribing Service UK. MeReC Bulletin Volume 21 No 5: Improving outcomes in type 2 diabetes. National Institute for Health and Clinical Excellence (NICE), June 2011. http://www.npc.nhs.uk/merec/cardio/diabetes2/merec_bulletin_vol21_no5.php (accessed 25 July 2012).